Latest Mesothelin Stories
The Mesothelioma Applied Research Foundation (Meso Foundation) congratulates former Science Advisory Board member and researcher at the National Cancer Institute, Raffit Hassan, MD, for receiving
The first phase II trial of an experimental mesothelioma drug contains good news for patients with unresectable mesothelioma. Raleigh, NC (PRWEB) October 09,
Researchers comparing the mesothelioma biomarkers mesothelin and fibulin-3 say mesothelin is still the most effective marker for diagnosis but fibulin-3 has another use. Raleigh,
Japanese researchers report good results with a new, more sensitive test for a key mesothelioma biomarker. Raleigh, NC (PRWEB) July 28, 2014 Scientists
Top mesothelioma researchers say an immunotoxin may have the power to significantly improve the effectiveness of chemotherapy in patients with malignant pleura mesothelioma. Raleigh,
Japanese cancer researchers say a simple blood test could help pinpoint the people at highest risk for mesothelioma in a large group of at-risk workers. Raleigh,
The Mesothelioma Applied Research Foundation announced that Dr.
A promising study was recently published reporting that targeted chemotherapy delivers cancer-fighting drugs directly into mesothelioma cells, while leaving healthy cells intact. St.
A team of international researchers say “turning off” the gene for mesothelin slows the spread of mesothelioma and sensitizes cells to cisplatin therapy. Raleigh,
A study of Italian workers finds that the mesothelioma biomarker SMRP will not help detect the disease earlier. Raleigh, NC (PRWEB) January 14, 2014